Global COVID-19 Overcoming Collaboration Group
‘IVRA’ Launched, “Proposed Treatment Guide”
Medical staff and scholars from over 30 countries around the world formed the International Virus Research Alliance (IVRA), a joint collaboration for the treatment of COVID-19, and began activities.
On the 29th, IVRA held a conference at COEX attended by advisory committee members consisting of ambassadors and commercial officers from each country, and domestic and foreign medical experts. Members presented treatment cases for confirmed COVID-19 patients and suggested treatment options to move toward 'With Corona'.
This is the world's first conference held to actively respond to 'With Corona' in the future by gathering medical staff and scholars from around the world who have experienced the limitations of vaccines to terminate COVID-19.
Dr. Yoo Seung-mo (Chairman of the Health and Healthcare Subcommittee of the Chungcheongnam-do External Cooperation Strategy Committee) and Yonsei Severance Professor, Lee Kang-hyun (former Dean of Yonsei Severance Wonju University) were appointed as the first IVRA organizing committee chairs, and through a video, Chungcheongnam-do Governor, Yang Seung-jo and Mohamed Jinna of the World Halal Federation (UNWHD) gave the congratulatory speech on behalf of the president.
In Korea, Ambassadors from Honduras to Korea and Sri Lanka to Korea participated, as well as Commercial Attaché Claudia from Romania, Commercial Attaché Philip Winkler from Austria, Permanent Attaché Daniela Petrova from Bulgaria, Attaché Bwanga Kapumpa from Zambia, Permanent Attaché Ahmed Amawi from Egypt, Permanent Attaché Win Pa Pa Thu from Myanmar, and Jose MA from the Philippines. Commercial Director Jojie and Cambodian Commercial Director Khath Chen attended.
Advisory members include former Dankook University Medical Center Director Park Woo-seong (Cancer Center Promotion Committee Chair), Catholic University Medical School Professor Jang Hong-seok, Yonsei University and Wonju University Professor Hwang Seong-oh, Catholic University Medical School Professor Kang Young-nam, Chung-Ang University Medical School Professor Jeong Yun-jae, Soonchunhyang University Medical School Professor Kim Ho-jung, Kyung Hee University University Professor Lee Hyeong-min, and Bundang Jesaeng Hospital. Center Director Kim Young-sik, Internal Medicine Director Jeong Young-ho, Yonsei Line Clinic Director An Seong-hwan, Pangyo Yonsei Clinic Director Shin Hyeong-jin, Korean Society of Balanced Medicine President Kim Gyeong-jin, former Integrative Oncology Association President Choi Nak-won, GBA Korea President Oh Sinan Ozturk, Asian Economic Development Committee Chairman Yoon Seok-heon, former Food and Drug Administration Commissioner Kim Jin-soo, IND CEO Jang Chang-don, and Eunseong Medical Foundation CEO Jeong Ho-jae. A total of 50 medical experts and prominent figures were appointed.
Among the contents announced at this IVRA, the results of treatment of COVID-19 patients using AdipoLABs' high-frequency hyperthermia cancer treatment device 'REMISSION 1℃' conducted by Professor Jang Hong-seok's team at Seoul St. Mary's Hospital and Seosan Medical Center attracted abundant attention.
IVRA Vice Chairman Kim Seon-man, who attended the event on this day, said, “Although the number of patient treatment cases is small, considering that the U.S. Centers for Disease Control and Prevention (CDC) recommends that the negative standard be set at a CT value of 29.5 or higher, it is possible to prevent COVID-19 using ‘REMISSION 1℃’. “It is obvious that the patient’s treatment result showed a CT value of 32 or higher,” he said. “If ‘Remission 1℃’ is applied globally, we can eliminate the contagiousness of COVID-19 patients and return to daily life early.”
IVRA Chairman Yoo Seung-mo (Chairman of the Health and Health Subcommittee of the Chungcheongnam-do Regional Economic and Diplomacy Strategy Committee) said, “COVID-19 is not a problem limited to a specific country and mutations continue,” adding, “We are looking at the possibility of treatment through immunity rather than through existing diagnosis and vaccines.” “As we have confirmed, today’s conference may not just stop at one small success but provide whole new opportunity for the future of Korea,” he said.
Sung-ho Han, CEO of AdipoLABs and the domestic corporate representative of IVRA, said, “Even amidst the domestic and foreign economic difficulties due to the COVID-19 pandemic, REMISSION 1℃ has improved the health of many patients.” He added, “Hyperthermia therapy increases immunity to treat the COVID-19 virus.” “We have achieved meaningful results and hope that this donation will serve as a chance to prove the effectiveness of immunotherapy for many patients infected with the virus.”
